Literature DB >> 14510741

Review article: colorectal cancer chemotherapy.

S Gill1, R R Thomas, R M Goldberg.   

Abstract

Colorectal cancer is a leading cause of cancer death world-wide. There have been important advances in the chemotherapeutic management of colorectal cancer as a result of a deliberate collaborative process of well-designed clinical trials. From the earlier standard of 5-fluorouracil-based therapy alone, the recent availability of newer agents, including capecitabine, irinotecan and oxaliplatin, has significantly expanded the options available for the management of patients with advanced colorectal cancer, with consequent improvements in survival. For patients with resected, high-risk, localized disease, adjuvant systemic chemotherapy improves survival. The identification of new chemotherapy regimens, the use of predictive testing and the integration of novel targeted therapies with cytotoxic chemotherapies are areas of active clinical investigation. A review of the chemotherapeutic management of colorectal cancer is presented.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14510741     DOI: 10.1046/j.1365-2036.2003.01735.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  24 in total

1.  Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1.

Authors:  Markus Wagner; Vincent Roh; Michael Strehlen; Alexander Laemmle; Deborah Stroka; Bernhard Egger; Markus Trochsler; Kelly K Hunt; Daniel Candinas; Stephan A Vorburger
Journal:  J Gastrointest Surg       Date:  2009-06-30       Impact factor: 3.452

Review 2.  Development and progression of colorectal neoplasia.

Authors:  Upender Manne; Chandrakumar Shanmugam; Venkat R Katkoori; Harvey L Bumpers; William E Grizzle
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

3.  Smad4 and epithelial-mesenchymal transition proteins in colorectal carcinoma: an immunohistochemical study.

Authors:  M Ioannou; E Kouvaras; R Papamichali; M Samara; I Chiotoglou; G Koukoulis
Journal:  J Mol Histol       Date:  2018-02-21       Impact factor: 2.611

Review 4.  How may anticancer chemotherapy with fluorouracil be individualised?

Authors:  Su-arpa Ploylearmsaeng; Uwe Fuhr; Alexander Jetter
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 5.  Germline oncopharmacogenetics, a promising field in cancer therapy.

Authors:  Chiara Pesenti; Milena Gusella; Silvia M Sirchia; Monica Miozzo
Journal:  Cell Oncol (Dordr)       Date:  2015-01-09       Impact factor: 6.730

Review 6.  Mechanisms of drug resistance in colon cancer and its therapeutic strategies.

Authors:  Tao Hu; Zhen Li; Chun-Ying Gao; Chi Hin Cho
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

7.  Biglycan promotes the chemotherapy resistance of colon cancer by activating NF-κB signal transduction.

Authors:  Bin Liu; Tonghong Xu; Xinning Xu; Yuzhu Cui; Xiaojing Xing
Journal:  Mol Cell Biochem       Date:  2018-05-14       Impact factor: 3.396

8.  The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy.

Authors:  Niels Halama; Sara Michel; Matthias Kloor; Inka Zoernig; Thora Pommerencke; Magnus von Knebel Doeberitz; Peter Schirmacher; Jürgen Weitz; Niels Grabe; Dirk Jäger
Journal:  Cancer Immun       Date:  2009-02-19

9.  Local staging and assessment of colon cancer with 1.5-T magnetic resonance imaging.

Authors:  Chris Hunter; Helena Blake; Nelesh Jeyadevan; Muti Abulafi; Ian Swift; Paul Toomey; Gina Brown
Journal:  Br J Radiol       Date:  2016-05-26       Impact factor: 3.039

10.  Berbamine suppresses cell viability and induces apoptosis in colorectal cancer via activating p53-dependent apoptotic signaling pathway.

Authors:  Heng Zhang; Yunping Jiao; Chunyang Shi; Xiao Song; Ying Chang; Yong Ren; Xiaolin Shi
Journal:  Cytotechnology       Date:  2017-09-30       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.